Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2023
Context: The filing addresses counterparty risk concerns following the collapse of Silicon Valley Bank, specifically confirming the company's exposure status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure regarding banking relationships rather than a financial performance statement.
Material Changes
No material changes to financial performance or operations were reported. The filing confirms the company's current status regarding banking deposits:
- Recursion Pharmaceuticals, Inc. does not hold any deposits or securities at Silicon Valley Bank.
- The company maintains no accounts at Silicon Valley Bank.
Outlook, Risks, and Management Commentary
Management Commentary: The company is currently evaluating counterparty risk across its banking relationships.
Risk Assessment: Management has discovered no material risk at this time related to the Silicon Valley Bank situation.
Unusual Items: The filing is a proactive disclosure under Regulation FD to clarify the company's lack of exposure to a specific financial institution.
Investor Verification Checklist
- Verify the company's total cash and cash equivalents in recent 10-Q or 10-K filings to assess overall liquidity.
- Confirm the list of primary banking partners to understand remaining counterparty exposure.
- Monitor subsequent filings for updates on the broader counterparty risk evaluation mentioned by management.